[144] Arcutis Biotherapeutics, Inc. SEC Filing
Rhea-AI Filing Summary
Arcutis Biotherapeutics submitted a Form 144 notice to sell 4,096 shares of Common Stock, with the filing dated 06/15/2026. The filing lists underlying grants described as stock option exercises (counts: 822, 1,019, 2,255) tied to earlier grant dates and shows two recent sales by Howard Welgus of 10,000 and 7,144 shares during April–May 2026.
Positive
- None.
Negative
- None.
Insights
Form 144 notifies the market of proposed insider sales and lists recent dispositions.
The filing identifies 4,096 shares of Common Stock to be sold pursuant to notice dated 06/15/2026. It also records underlying option exercises dated 11/20/2019, 05/31/2023, and 06/14/2024 with counts of 822, 1,019, and 2,255.
Two recent dispositions by Howard Welgus are recorded: 10,000 shares on 04/01/2026 (proceeds $238,800) and 7,144 shares on 05/01/2026 (proceeds $164,219.71). Timing and execution details beyond the notice are not provided in the excerpt.